Red cell storage for 56 days in modified DPD-adenine. An in vitro evaluation.
The modified CPD-adenine anticoagulants CPDA-2 and CPDA-3 were developed to improve red blood cell storage to 35 days, since CPDA-1 was found marginal at 35 days in high hematocrit samples. In this study red blood cell storage was extended to 56 days. In vitro correlates of viability were monitored to determine the feasibility of evaluating in vivo the ability of CPDA-2 and CPDA-3 to extend storage past 35 days. The data suggest that red blood cells stored up to 56 days may have acceptable viability, providing the possibility of extended storage for the military and certain special civilian situations.
D019794:2,3-Diphosphoglycerate; D000225:Adenine / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000097:blood; D000925:Anticoagulants / Q000494:pharmacology; D001786:Blood Glucose; D001793:Blood Preservation; D002951:Citrates / Q000494:pharmacology*; D004163:Diphosphoglyceric Acids / Q000097:blood; D004912:Erythrocytes / Q000502:physiology*; D005947:Glucose / Q000494:pharmacology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D013997:Time Factors
D000925:Anticoagulants; D001786:Blood Glucose; D002951:Citrates; D004163:Diphosphoglyceric Acids; D019794:2,3-Diphosphoglycerate; C007077:citrate phosphate dextrose; D000255:Adenosine Triphosphate; D005947:Glucose; D000225:Adenine